151272-78-5
Chemical Structure
Teverelix
Synonym(s): EP 24332
- CAS No.: 151272-78-5
- Formula:C74H100ClN15O14
- Molecular Weight:1459.13
IUPAC Name: (S)-1-(N2-N2-((R)-2-((R)-2-((R)-2-acetamido-3-(naphthalen-2-yl)propanamido)-3-(4-chlorophenyl)propanamido)-3-(pyridin-3-yl)propanoyl)-L-seryl-L-tyrosyl-N6-carbamoyl-D-lysyl-L-leucyl-N6-isopropyl-L-lysyl)-N-((R)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carbo
InChIKey: NOENHWMKHNSHGX-IAOPALDYSA-N
SMILES: OC(C=C1)=CC=C1C[C@H](NC([C@H](CO)NC([C@@H](CC2=CN=CC=C2)NC([C@H](NC([C@H](NC(C)=O)CC3=CC4=CC=CC=C4C=C3)=O)CC5=CC=C(Cl)C=C5)=O)=O)=O)C(N[C@H](CCCCNC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCNC(C)C)C(N6[C@@H](CCC6)C(N[C@H](C)C(N)=O)=O)=O)=O)=O)=O
Biological Activity: Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Teverelix | Teverelix (EP 24332) is a GnRH antagonist. Teverelix binds competitively and reversibly to GnRH receptors, thereby suppressing the release of LH and FSH. Teverelix can be used in the research of prostatic hyperplasia, endometriosis, and prostate cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. MacLean CM, et al. Pharmacokinetic, Safety, and Pharmacodynamic Properties of Teverelix Trifluoroacetate, a Novel Gonadotropin-Releasing Hormone Antagonist, in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2022 Feb;11(2):257-269. [Content Brief]
- [2]. Sperduti S, et al. GnRH Antagonists Produce Differential Modulation of the Signaling Pathways Mediated by GnRH Receptors. Int J Mol Sci. 2019 Nov 7;20(22):5548. [Content Brief]
Keywords
